Everest Medicines reported earnings results for the full year ended 31 December 2020. Net loss for the year ended 31 December 2020 increased to RMB 5,658.2 million, from RMB 214.5 million for the year ended 31 December 2019, primarily due to the loss of RMB 4,938.0 million in fair value change in financial instruments issued to investors.